Core Insights - Pembina Pipeline reported a fourth-quarter 2025 earnings of CAD 489 million and Adjusted EBITDA of approximately CAD 1.075 billion, with a full-year Adjusted EBITDA of CAD 4.289 billion, reflecting a record annual volume increase of about 3% compared to 2024 [4][3][7] - The decline in fourth-quarter Adjusted EBITDA by CAD 179 million, or 14%, year-over-year was primarily due to a lower contribution from marketing and new ventures, a new toll structure on the Alliance Pipeline, and a specific capital recovery that benefited the previous year [2][7] - Management reiterated 2026 Adjusted EBITDA guidance of CAD 4.125–4.425 billion, indicating a compound annual growth rate of approximately 5% in fee-based Adjusted EBITDA per share from 2023 to 2026 [6][11] Financial Performance - For the full year, Pembina achieved earnings of CAD 1.694 billion and adjusted cash flow from operating activities of CAD 2.854 billion, or CAD 4.91 per share [3] - Fourth-quarter results showed a decline in revenue from certain pipeline assets due to capital recoveries recognized in the previous year and lower interruptible volumes on the Goshen Pipeline [1][7] Growth Initiatives - Several growth projects are on time and on or under budget, including the RFS IV, Wapiti expansion, and K3 cogeneration, with more than 200,000 barrels per day of pipeline capacity added [5][10] - The Cedar LNG project is over 35% complete, with long-term agreements signed to enhance financial contributions and validate demand for Canadian West Coast LNG [17] Contracting and Pipeline Expansions - Pembina renewed existing contracts and signed new contracts totaling over 200,000 barrels per day of conventional pipeline transportation capacity, including substantial renewals on the Peace Pipeline system [13][14] - The company announced expansions aimed at condensate and NGL transportation demand, with a total investment of CAD 625 million for three pipeline expansions [15] Future Outlook - Pembina expects its 2026 year-end debt-to-Adjusted EBITDA ratio to be about 3.7x to 4.0x, with 2026 anticipated as the peak year for leverage [12] - Management is focused on optimizing capital deployment based on customer growth and has plans for further expansions in response to demand [16][19]

Core Insights - The company achieved record new member additions with 371,000 new members in 2025 and reported a 14% increase in written premiums, indicating strong growth across its ecosystem [1][6] - Management emphasized a focus on top-line growth while efficiently translating revenue into profits and cash flow, with a compounded annual revenue growth rate of 23% since going public [2][6] - The company exceeded its 2025 expectations with a 17% revenue growth and a 91% increase in net income, attributed to record new business volume and operational efficiencies [3][6] Financial Performance - For the fourth quarter, revenue increased by 19% to $357 million, with net income rising sharply by 238% to $29 million [10][12] - Operating cash flow for the year increased by 24% to $219 million, with a retention rate of 89% in Q4 [2][6] - The company reported a quarterly loss ratio of 31%, positively impacted by a $21 million reserve reduction [11][19] Marketplace Growth - Marketplace revenue more than doubled in 2025, increasing by 119% to $119 million, driven by expansion into Europe and strong auction performance [5][14] - Total vehicle transactions reached $624 million, with significant contributions from financing activity and online sales [14] - Management noted that while Marketplace growth is strong, it is more variable compared to insurance, making forecasting less precise [15] Strategic Changes - The company signed a new fronting deal with Markel, allowing it to retain 100% of premium, which is expected to enhance long-term underwriting profitability but will result in a non-cash amortization of approximately $190 million in 2026 [6][8] - The new arrangement is anticipated to create a "step function increase" in potential underwriting profitability and investment income [8] - Management cautioned that GAAP net income for 2026 will be negatively impacted by transitional accounting items related to the new fronting structure [4][16] 2026 Outlook - For 2026, the company projects written premium growth of 15% to 16%, driven by new business counts and the evolved Markel arrangement [16][18] - Despite the expected growth in written premiums, revenue is forecasted to be between $1.28 billion and $1.3 billion, lower than 2025 due to the elimination of commission revenue [17] - GAAP net income is guided to be negative, ranging from $41 million to $51 million, while adjusted EBITDA is expected to be between $236 million and $247 million [18]

Year to date sales growth of Dream Water® E-commerce of 26% offset by a decline of Dream Water® Retail of 4% compared to same period last yearYear to date sales growth of LivRelief™ E-commerce of 28 % offset by a decline in LivRelief™ Retail of 29% compared to same period last yearVancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health an ...

Earnings Conference Call 4Q25 and FY2025 February 27, 2026 Disclaimer Important information concerning this presentation This presentation, prepared by Nexa Resources S.A. (herein referred to as "Nexa Resources", "Nexa", or the "Company"), is solely for informational purposes. Disclosure of this presentation, its contents, extracts or abstracts to third parties is not authorized without express and prior written consent from the Company. This Presentation contains certain forward-looking information and for ...

COVINGTON, La.--(BUSINESS WIRE)--Globalstar, Inc. (Nasdaq: GSAT) ("Globalstar" or the "Company") today announced its financial results for the fourth quarter and year ended December 31, 2025. Globalstar reported full year revenue of $273.0 million, representing a 9% increase from 2024, and lower net loss, delivering an Adjusted EBITDA* margin of 50%, reflecting disciplined execution and continued progress across its business. Both total revenue and Adjusted EBITDA margin were in line with guidance. Advanced ...

Supplemental Information Fourth Quarter 2025 Disclaimers IN GENERAL . Thisdisclaimerapplies tothisdocumentand theverbal or writtencommentsof any personpresentingit. Thisdocument,takentogetherwithany suchverbal or writtencomments,is referredtohereinas the "Presentation." Theinformationcontainedon, or accessible through,any websitesincludedin thisPresentationis notincorporatedby referenceinto,and shouldnotbe considereda partof, thisPresentation. FORWARD -LOOKING STATEMENTS . Certainstatementsin thisPresentati ...

Core Insights - Treace Medical Concepts, Inc. reported financial results for Q4 and full-year 2025, highlighting a shift in product sales and expectations for future growth [1][3][4]. Financial Performance - Q4 2025 revenue was $62.5 million, a 9% decrease from $68.7 million in Q4 2024, primarily due to a shift towards lower-priced bunion kits [4]. - Gross profit for Q4 2025 was $50.4 million, with a gross margin of 80.6%, slightly down from 80.7% in Q4 2024 [4]. - Total operating expenses in Q4 2025 were $56.3 million, up 1% from $55.7 million in Q4 2024 [5]. - The net loss for Q4 2025 was $(9.4) million, or $(0.15) per share, compared to a net loss of $(0.5) million, or $(0.01) per share, in Q4 2024 [5]. - Adjusted EBITDA for Q4 2025 was $6.2 million, down from $11.1 million in Q4 2024 [5]. Full-Year Results - Full-year 2025 revenue was $212.7 million, a 2% increase from $209.4 million in 2024 [6]. - Gross profit for the full year was $169.8 million, with a gross margin of 79.8%, down from 80.4% in 2024 [6]. - Total operating expenses for 2025 were $223.9 million, slightly down from $224.0 million in 2024 [6]. - The full-year net loss was $(59.0) million, or $(0.93) per share, compared to $(55.7) million, or $(0.90) per share, in 2024 [7]. - Adjusted EBITDA loss for 2025 was $(3.9) million, significantly improved from $(11.0) million in 2024 [7]. Operational Highlights - The company increased its active surgeon base by 202, ending 2025 with 3,337 active surgeons, a 6% increase year-over-year [8]. - The company broadened its global patent portfolio to 135 granted patents and 199 pending applications [8]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities totaled $48.4 million as of December 31, 2025 [9]. - The company reduced cash usage by 46% to $27.3 million in 2025 compared to $50.5 million in 2024 [8][9]. 2026 Financial Outlook - The company projects full-year 2026 revenue guidance of $200 million to $212 million, indicating a decline of 6% to 0% compared to 2025 [10]. - Expected Adjusted EBITDA loss for 2026 is projected to be between $(4.0) million and $(6.0) million [10]. - Anticipated reduction in cash usage for 2026 is approximately 50% compared to 2025 [10].

LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2025 and initiated full year 2026 Revenue and Adjusted EBITDA1 guidance. Fourth Quarter 2025 Financial Highlights(note: all figures represent continuing operations and exclude the Community Living b ...

Financial Data and Key Metrics Changes - Teknova achieved a top-line revenue growth of 7% in 2025 compared to 2024, with Q4 revenue increasing by 8% to $10.0 million from $9.3 million in Q4 2024 [5][15][16] - Full year revenue for 2025 reached $45 million, up from $37.7 million in 2024 [15][16] - Free cash outflow improved from $13.5 million in 2024 to $9.8 million in 2025, which was better than the guidance of less than $12 million [15][30] Business Line Data and Key Metrics Changes - Lab Essentials revenue for 2025 was $31.0 million, a 7% increase from $28.9 million in 2024, with Q4 revenue remaining stable at $6.8 million [16][17] - Clinical Solutions revenue grew by 47% in Q4 2025 to $2.7 million from $1.9 million in Q4 2024, and for the full year, it increased by 8% to $7.7 million from $7.1 million in 2024 [18][19] - The number of Clinical Solutions customers increased from 48 in 2024 to 60 in 2025, while average revenue per customer decreased by 14% to $128,000 [18][19] Market Data and Key Metrics Changes - The company reported a 25% increase in the number of customers actively buying clinical products, reaching 60 customers [5][6] - Teknova supports at least 70 therapies, with 5 in phase II or later and 12 in phase I, indicating a growth in later-stage therapies [6][7][50] Company Strategy and Development Direction - Teknova aims to become a critical supplier of GMP-grade reagents and expand its presence in high-growth market segments like sequencing and cancer screening [6][9] - The company plans to invest approximately $2 million annually in commercial capabilities to accelerate revenue growth, particularly in emerging segments [10][11] - Teknova expects to achieve adjusted EBITDA positivity by the end of 2027, with a revenue target of $52 million to $57 million [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term outlook for end markets, citing an uptick in biotech funding and potential FDA approvals for therapies in 2027 [11][12][33] - The company anticipates that increased biotech funding will positively impact revenue, particularly in custom biopharma products [40][46] - Management highlighted the importance of maintaining a strong cost structure while preparing for growth investments [27][30] Other Important Information - Gross margin improved to 33.2% for the full year 2025, up from 19.2% in 2024, driven by higher revenue and manufacturing efficiency [20][21] - Operating expenses decreased to $30.4 million in 2025 from $33.4 million in 2024, reflecting cost-cutting measures [22][23] Q&A Session Summary Question: Growth drivers in emerging segments - Management discussed the potential of sequencing, spatial genomics, and cancer screening as growth drivers, emphasizing the need for commercial investment to enhance customer relationships and brand awareness [35][36] Question: Revenue segments affected by biotech funding - Management indicated that custom biopharma products are most affected by biotech funding changes, historically representing about 25% of revenue [39] Question: Adjusted EBITDA target for 2027 - Management clarified that achieving positive adjusted EBITDA by the end of 2027 requires reaching a run rate of approximately $13 million to $14 million per quarter [43][45] Question: RUO to GMP customer transition - Management confirmed supporting 60 clinical customers and highlighted the significant revenue increase expected as therapies progress through clinical phases [49][50] Question: Average revenue ramp-up time for new customers - Management noted that the ramp-up time is therapy-dependent, with clinical trials potentially taking several years, but expressed optimism about increasing average revenue as therapies advance [54][56] Question: Impact of FDA guidance on drug development timeframes - Management acknowledged that shorter drug development timelines could positively impact business, especially as more therapies reach commercialization [58][61]

Alpha Teknova (NasdaqGM:TKNO) Q4 2025 Earnings call February 26, 2026 05:30 PM ET Speaker2Good day, and welcome to Teknova's fourth quarter and full year 2025 financial results call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, pres ...